Health Information Center

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs. ( http://www.bharatbook.com/detail.asp?id=68637&rt=F-Hoffmann-La-Roche-Ltd-PharmaVitae-Profile.html )

Roche has invested roughly CHF190m ($183m) at two production sites to manufacture devices that will allow patients to self-administer a subcutaneous formulation of Herceptin (trastuzumab; Roche/Genentech/Chugai). Continue reading ‘Roche: novel Herceptin formulation promises greater convenience’ »

The report provides market landscape, competitive landscape and market trends information on four ophthalmic devices market categories – cataract surgery devices, refractive surgery devices, vision care, and ophthalmic diagnostic equipment. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.( http://www.bharatbook.com/detail.asp?id=133653&rt=The-Future-of-Ophthalmic-Devices-Market-Forecasts-and-Growth-Opportunities-to-2016-The-Vision-Care-Segment-Emerges-as-a-Key-Revenue-Generator.html )

The Global Ophthalmic Devices Market to Reach $28 billion by 2016The global ophthalmic devices market is forecast to reach $28 billion by 2016 with a Compound Annual Growth Rate (CAGR) of 2.5% from 2009-2016. The market is expected to be driven by a huge population suffering from vision problems, the availability of reimbursement for a majority of the devices and surgeries and the direct to consumer approach of the companies. The aging population is also an important growth driver for the market. The availability and accessibility of treatment for a majority of vision problems is also leading to increased patient demand and a subsequent growth in the market. This report provides key data, information and analysis on the global ophthalmic devices market.

The US to Continue to be the Biggest Ophthalmic Devices Market
The US is the biggest market for ophthalmic devices, contributing 26% towards the global market in 2009, and this contribution is expected to increase to 27% in 2016. The US ophthalmic devices market was valued at $6 billion in 2009 and is forecast to grow at a CAGR of 3.4% to reach $7.6 billion in 2016. The market is expected to be driven by the high prevalence of vision problems, the increasing contribution of employees and employers for vision care coverage and the availability and easy accessibility of the latest medical interventions for affected patients. Continue reading ‘Vision Care Market Remains The Largest Category In The Global Ophthalmic Devices Market’ »

US healthcare reform: a double-edged sword

The US House of Representatives has passed legislation paving the way for major healthcare system reform designed to substantially decrease the number of individuals without health insurance. Despite its potential benefits, it believes that the reform is a mixed blessing for the pharmaceutical industry as cost-containment pressures are set to intensify in the long term. ( http://www.bharatbook.com/detail.asp?id=134206&rt=Pharmaceutical-Licensing-Overview.html )

The landmark bill will overhaul the US healthcare system, aiming to reduce the number of individuals without healthcare insurance, improve access to healthcare and curb escalating costs. The bill focuses on health insurance system reform, specifically: expanding Medicaid insurance coverage for the poor; implementing stricter rules for private health insurers; outlining the creation of an individual mandate to purchase insurance; and introducing health insurance premium subsidies. Continue reading ‘US healthcare reform: a double-edged sword’ »

Bausch & Lomb Incorporated-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Bausch & Lomb Incorporated-Company Report’ »

Pfizer’s novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug’s analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, it expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy. ( http://www.bharatbook.com/detail.asp?id=130154&rt=Stakeholder-Insight-Osteoarthritis-Drug-development-lags-behind-rising-osteoarthritis-population.html )

Pfizer has announced positive results from three Phase II trials in pain at the American Academy of Pain Medicine’s 26th Annual Meeting. The randomized, double-blind, placebo-controlled six-week trials in patients with chronic low back pain (CLBP) and interstitial cystitis receiving a single intravenous infusion of tanezumab (200mcg/kg) met their primary endpoints of significantly superior pain relief over placebo. Continue reading ‘Pfizer's novel NGF pain drug is potential game changer’ »

Oncology Market Leaders – Analyses and Outlook – 2010-2025

Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. ( http://www.bharatbook.com/detail.asp?id=132312&rt=Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html )

The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. Continue reading ‘Comprehensive Analysis Of The Oncology Market Sector’ »

EASD 2009: Lantus defended amid allegations of increased cancer risk

It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )

Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.

It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »

Axcan Pharma Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Axcan Pharma Inc.-Company Report’ »

Cancer Head and Neck Cancer Therapy Area Pipeline Report

This report contains detailed information on the head and neck cancer drug pipeline. This report provides insight into the pipeline status of head and neck cancer drugs by company and by stage as well as a summary of the latest news and developments in this area. ( http://www.bharatbook.com/detail.asp?id=126756&rt=Cancer-Head-and-Neck-Cancer-Therapy-Area-Pipeline-Report.html )

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area. Continue reading ‘Cancer Head And Neck Cancer Therapy Area Pipeline Report’ »

Alliance Pharma plc-Company Report

Bharatbook.com added a new report on “Alliance Pharma plc-Company Report” into its market report catalogue for reselling.

Alliance Pharma plc-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Alliance Pharma plc-Company Report’ »